Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26718859 | 0.86 | ALDH1A1 (0.52) | ALDH1A1MAPTPOLBSMN1; SMN2GAA | |
| SCHEMBL2606775 | 0.86 | ALDH1A1 (0.52) | ALDH1A1MAPTPOLBSMN1; SMN2GAA | |
| SCHEMBL25030971 | 0.82 | POLB (0.31) | ALDH1A1MAPTPOLB | |
| SCHEMBL18810734 | 0.82 | ALDH1A1 (0.38) | ALDH1A1MAPTPOLBSMN1; SMN2GAA | |
| SCHEMBL4570868 | 0.79 | ALDH1A1 (0.36) | ALDH1A1MAPTPOLBSMN1; SMN2GAA | |
| SCHEMBL18844877 | 0.76 | GAA (0.31) | GAAL3MBTL1 | |
| SCHEMBL16171239 | 0.76 | MDM2 (0.41) | ALDH1A1GAAL3MBTL1 | |
| SCHEMBL681668 | 0.76 | — | — | |
| SCHEMBL18458286 | 0.76 | MDM2 (0.41) | ALDH1A1GAAL3MBTL1 | |
| SCHEMBL2600363 | 0.76 | MDM2 (0.41) | ALDH1A1GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | ATHOS THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | ATHOS THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11136338-B2 | Fused thiazolopyrimidine derivatives as MNKs inhibitors | LIFEARC (GB) | 2021-10-05 | — | — | US | disclosed |
| US-20210137910-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-05-13 | — | — | US | disclosed |
| US-11001594-B2 | Heterocyclic modulators of HIF activity for treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-05-11 | — | — | US | disclosed |
| WO-2021083011-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVE AND USE THEREOF | 北京伯汇生物技术有限公司 | 2021-05-06 | — | — | WO | disclosed |
| WO-2021031952-A1 | OXYGEN-SUBSTITUTED SIX-MEMBERED RING PYRIMIDINE COMPOUND, PREPARATION METHOD AND MEDICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2021-02-25 | — | — | WO | disclosed |
| US-10888554-B2 | Salts of heterocyclic modulators of HIF activity for treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200247822-A1 | Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors | ASTRAZENECA UK LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| US-20200171017-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-06-04 | — | — | US | disclosed |
| US-9018380-B2 | Heterocyclic modulators of HIF activity for treatment of disease | Boar of Regents, The University of Texas System (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140066424-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center (US) | 2014-03-06 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20100041886-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | BUETTELMANN BERND | 2010-02-18 | — | — | US | disclosed |
| US-20100041886-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | BUETTELMANN BERND | 2010-02-18 | — | — | US | disclosed |
| US-7618973-B2 | Isoxazolo-pyrazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618973-B2 | Isoxazolo-pyrazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20090143407-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
| US-20090143407-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143407-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | GABRA5, CHRNA5, GABRA4 | ALDH1A1 1772/4885MAPT 264/4885POLB 4381/4885 |
| US-20200171017-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, VHL, HIF1A | ALDH1A1 572/4885MAPT 4662/4885POLB 1604/4885 |
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | SSB, HLA-DRB1, UACA | ALDH1A1 3670/4885MAPT 4698/4885POLB 1646/4885 |
| US-20200247822-A1 | Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors | MAPT, TTBK1, TTBK2 | ALDH1A1 3442/4885MAPT 1/4885POLB 1777/4885 |
| US-20140066424-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, HIF1A, EGLN3 | ALDH1A1 546/4885MAPT 4777/4885POLB 1509/4885 |
| US-10888554-B2 | Salts of heterocyclic modulators of HIF activity for treatment of disease | HIF1AN, VHL, HIF1A | ALDH1A1 572/4885MAPT 4662/4885POLB 1604/4885 |
| US-20210137910-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, VHL, HIF1A | ALDH1A1 572/4885MAPT 4662/4885POLB 1604/4885 |
| US-11136338-B2 | Fused thiazolopyrimidine derivatives as MNKs inhibitors | MAPT, TTBK1, TTBK2 | ALDH1A1 3442/4885MAPT 1/4885POLB 1777/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | ALDH1A1 534/4885MAPT 2512/4885POLB 1198/4885 |
| US-20100041886-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | GABRA5, CHRNA5, GABRA4 | ALDH1A1 1772/4885MAPT 264/4885POLB 4381/4885 |
| US-11001594-B2 | Heterocyclic modulators of HIF activity for treatment of disease | HIF1AN, HIF1A, EGLN3 | ALDH1A1 546/4885MAPT 4777/4885POLB 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.